Arkolith/Insider Trading/OLMA/Form 4

BVF Partners OS Ltd.

DirectorOlema Pharmaceuticals, Inc. (OLMA) · full profile →Form 4 · filed Jan 14, 2025
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
6
3 non-derivative · 3 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Jan 10, 2025Disposed to issuer(D)162K——2.0M
Jan 10, 2025Disposed to issuer(D)235K——2.7M
Jan 10, 2025Disposed to issuer(D)23K——348K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Jan 10, 2025Grant(A)162K——2.6M
Jan 10, 2025Grant(A)235K——3.3M
Jan 10, 2025Grant(A)23K——336K

Transaction Codes

D
Disposition to the issuer
A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0000921895-25-000106) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML